164 related articles for article (PubMed ID: 31838956)
1. Effect of iron chelation therapy on EPO-STAT5 signalling pathway and EPO resistance in iron-overloaded low-risk myelodysplastic syndrome patients.
Zhang Y
Hematology; 2020 Dec; 25(1):1-10. PubMed ID: 31838956
[No Abstract] [Full Text] [Related]
2. [Iron chelation therapy and its influence on the alleviation of EPO resistance in MDS patients].
Zhang Y; Xiao C; Gu SC; Chang CK
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):1027-32. PubMed ID: 25130822
[TBL] [Abstract][Full Text] [Related]
3. To chelate or not to chelate in MDS: That is the question!
Zeidan AM; Griffiths EA
Blood Rev; 2018 Sep; 32(5):368-377. PubMed ID: 29602612
[TBL] [Abstract][Full Text] [Related]
4. Overcoming barriers to treating iron overload in patients with lower-risk myelodysplastic syndrome.
Zeidan AM; Pullarkat VA; Komrokji RS
Crit Rev Oncol Hematol; 2017 Sep; 117():57-66. PubMed ID: 28807236
[TBL] [Abstract][Full Text] [Related]
5. Iron chelation therapy in myelodysplastic syndromes: where do we stand?
Mitchell M; Gore SD; Zeidan AM
Expert Rev Hematol; 2013 Aug; 6(4):397-410. PubMed ID: 23991926
[TBL] [Abstract][Full Text] [Related]
6. Iron overload in lower international prognostic scoring system risk patients with myelodysplastic syndrome receiving red blood cell transfusions: Relation to infections and possible benefit of iron chelation therapy.
Wong CAC; Wong SAY; Leitch HA
Leuk Res; 2018 Apr; 67():75-81. PubMed ID: 29477023
[TBL] [Abstract][Full Text] [Related]
7. Erythropoietin-induced activation of STAT5 is impaired in the myelodysplastic syndrome.
Hoefsloot LH; van Amelsvoort MP; Broeders LC; van der Plas DC; van Lom K; Hoogerbrugge H; Touw IP; Löwenberg B
Blood; 1997 Mar; 89(5):1690-700. PubMed ID: 9057652
[TBL] [Abstract][Full Text] [Related]
8. Can iron overload in patients with lower-risk myelodysplastic syndromes be reduced using erythropoiesis-stimulating agents?
Tsang E; Leitch HA
Ann Hematol; 2016 Jan; 95(1):73-78. PubMed ID: 26453076
[TBL] [Abstract][Full Text] [Related]
9. [Effects of Abnormal Iron Metabolism on EPO-STAT5 Signaling Pathway in Anemia Patients].
Zhang Y; Han S; Guo C; Zhang QX; Chang CK
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Dec; 26(6):1726-1730. PubMed ID: 30501711
[TBL] [Abstract][Full Text] [Related]
10. [STAT5 phosphorylation in CD34(+)CD38(-)CD123(+) bone marrow cells of the patients with myelodysplastic syndrome].
Liu BN; Fu R; Wang HQ; Li LJ; Yue LZ; Ruan EB; Qu W; Liang Y; Wang GJ; Wang XM; Liu H; Wu YH; Song J; Xing LM; Guan J; Wang J; Shao ZH
Zhonghua Xue Ye Xue Za Zhi; 2012 Jun; 33(6):480-3. PubMed ID: 22967386
[TBL] [Abstract][Full Text] [Related]
11. Iron overload and chelation therapy in myelodysplastic syndromes.
Temraz S; Santini V; Musallam K; Taher A
Crit Rev Oncol Hematol; 2014 Jul; 91(1):64-73. PubMed ID: 24529413
[TBL] [Abstract][Full Text] [Related]
12. Guidelines for treating iron overload in myelodysplastic syndromes: a Taiwan consensus statement.
Ko BS; Chang CS; Chang MC; Chen TY; Chiou TJ; Chiu CF; Huang WL; Kao WY; Lan YJ; Lin SF; Tan TD; Tang JL; Tzeng CH; Wang PN; Yet SP; Tien HF
Int J Hematol; 2014 Jul; 100(1):7-15. PubMed ID: 24924953
[TBL] [Abstract][Full Text] [Related]
13. When is iron overload deleterious, and when and how should iron chelation therapy be administered in myelodysplastic syndromes?
Steensma DP; Gattermann N
Best Pract Res Clin Haematol; 2013 Dec; 26(4):431-44. PubMed ID: 24507819
[TBL] [Abstract][Full Text] [Related]
14. Analysis of hematopathology and alteration of JAK1/STAT3/STAT5 signaling axis in experimental myelodysplastic syndrome.
Daw S; Chatterjee R; Law A; Law S
Chem Biol Interact; 2016 Dec; 260():176-185. PubMed ID: 27725143
[TBL] [Abstract][Full Text] [Related]
15. Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis.
Leitch HA; Parmar A; Wells RA; Chodirker L; Zhu N; Nevill TJ; Yee KWL; Leber B; Keating MM; Sabloff M; St Hilaire E; Kumar R; Delage R; Geddes M; Storring JM; Kew A; Shamy A; Elemary M; Lenis M; Mamedov A; Ivo J; Francis J; Zhang L; Buckstein R
Br J Haematol; 2017 Oct; 179(1):83-97. PubMed ID: 28677895
[TBL] [Abstract][Full Text] [Related]
16. Deferasirox reduces oxidative DNA damage in bone marrow cells from myelodysplastic patients and improves their differentiation capacity.
Jiménez-Solas T; López-Cadenas F; Aires-Mejía I; Caballero-Berrocal JC; Ortega R; Redondo AM; Sánchez-Guijo F; Muntión S; García-Martín L; Albarrán B; Alonso JM; Del Cañizo C; Hernández-Hernández Á; Díez-Campelo M
Br J Haematol; 2019 Oct; 187(1):93-104. PubMed ID: 31172513
[TBL] [Abstract][Full Text] [Related]
17. Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron?
Leitch HA; Vickars LM
Hematology Am Soc Hematol Educ Program; 2009; ():664-72. PubMed ID: 20008252
[TBL] [Abstract][Full Text] [Related]
18. High expression of APAF-1 elevates erythroid apoptosis in iron overload myelodysplastic syndrome.
Gu S; Zhao Y; Guo J; Xu F; Fei C; Zhang X; Xiao C; Chang C; Li X
Tumour Biol; 2014 Mar; 35(3):2211-8. PubMed ID: 24142530
[TBL] [Abstract][Full Text] [Related]
19. Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy.
Leitch HA
Leuk Res; 2007 Dec; 31 Suppl 3():S7-9. PubMed ID: 18037416
[TBL] [Abstract][Full Text] [Related]
20. [Effects of Yisui Jiedu Recipe on JAK2-STAT5 signal transduction pathway in bone marrow hematopoietic cells from patients with myelodysplastic syndrome-refractory anemia].
Tian SL; Zhou YM; Huang T; Xue ZZ; He W
Zhong Xi Yi Jie He Xue Bao; 2008 Feb; 6(2):185-9. PubMed ID: 18241656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
